Parkinson's Disease: Current Treatment Options And Emerging Pharmacotherapies

Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is principally characterised by the loss of nigrostriatal dopaminergic neurons, but whose clinical and biological phenotype goes beyond dopamine deficiency. Motor features such as bradykinesia, rigidity, resting tremor and postural instability are accompanied by a wide range of non-motor features—such as cognition, mood, sleep, autonomic function, gastrointestinal function and pain. A multidimensional approach, which involves pharmacological, device-aided and rehabilitative treatments, is currently required for the treatment. Levodopa is the most effective motor disability (symptomatic) therapy but wearing off and dyskinesia occur often with long-term use. Dopamine agonists and MOA-B, COMT inhibitors, amantadine and adenosine A2A antagonism are complementary treatments, and newer delivery systems should aim to overcome pharmacokinetic issues and minimize fluctuations. Several new treatments are available to help treat advanced disease, such as continuous subcutaneous levodopa/carbidopa infusion, inhaled levodopa, and sublingual or injectable apomorphine. Recently, more interest has been generated in extended-release oral levodopa and selective dopamine D1/D5 receptor agonism, which are both now in late-stage development. Although much research has been conducted, there is no pharmacological therapy that has been conclusively proven to have disease modifying effects. New therapies are being developed to address some of the other mechanisms associated with the disease, such as aggregation and propagation of α-synuclein, dysfunction of glucocerebrosidase (GBA) and the lysosomes, leucine-rich repeat kinase 2 (LRRK2), neuroinflammation, and mitochondrial dysfunction and cellular metabolism. From a clinical perspective, the results have often been less convincing than from the preclinical studies. Several of the repurposed agents and GLP-1 receptor agonist and α-synuclein antibodies are examples of the challenges associated with moving mechanistic hypotheses into clinically meaningful slowing of progression. However, recent lixisenatide, ambroxol, ursodeoxycholic acid, LRRK2 inhibitors and prasenezumab trials have added valuable insights both in the biology and methodology of the field. The future of therapeutic development could be moving from treating the symptoms of a disease to modifying it, via the use of biomarker-driven and genetically defined trials. This review analyzes existing pharmacotherapies, novel delivery systems, and future pharmacologic options for improvement with a critical review of comparative efficacy, unmet challenges, unanswered controversies and priorities for continued research and development.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-16
DOI
https://doi.org/10.5281/zenodo.24271752
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Parkinson's Disease: Current Treatment Options And Emerging Pharmacotherapies

Manjinder Kaur, Mujeeb Ur Rehman*, Reenu, Puja Gulati et al.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Parkinson's Disease Mechanisms and Treatments
article

Parkinson's Disease: Current Treatment Options And Emerging Pharmacotherapies

Manjinder Kaur, Mujeeb Ur Rehman*, Reenu, Puja Gulati, Asha Juma Haji
article en

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is principally characterised by the loss of nigrostriatal dopaminergic neurons, but whose clinical and biological phenotype goes beyond dopamine deficiency. Motor features such as bradykinesia, rigidity, resting tremor and postural instability are accompanied by a wide range of non-motor features—such as cognition, mood, sleep, autonomic function, gastrointestinal function and pain. A multidimensional approach, which involves pharmacological, device-aided and rehabilitative treatments, is currently required for the treatment. Levodopa is the most effective motor disability (symptomatic) therapy but wearing off and dyskinesia occur often with long-term use. Dopamine agonists and MOA-B, COMT inhibitors, amantadine and adenosine A2A antagonism are complementary treatments, and newer delivery systems should aim to overcome pharmacokinetic issues and minimize fluctuations. Several new treatments are available to help treat advanced disease, such as continuous subcutaneous levodopa/carbidopa infusion, inhaled levodopa, and sublingual or injectable apomorphine. Recently, more interest has been generated in extended-release oral levodopa and selective dopamine D1/D5 receptor agonism, which are both now in late-stage development. Although much research has been conducted, there is no pharmacological therapy that has been conclusively proven to have disease modifying effects. New therapies are being developed to address some of the other mechanisms associated with the disease, such as aggregation and propagation of α-synuclein, dysfunction of glucocerebrosidase (GBA) and the lysosomes, leucine-rich repeat kinase 2 (LRRK2), neuroinflammation, and mitochondrial dysfunction and cellular metabolism. From a clinical perspective, the results have often been less convincing than from the preclinical studies. Several of the repurposed agents and GLP-1 receptor agonist and α-synuclein antibodies are examples of the challenges associated with moving mechanistic hypotheses into clinically meaningful slowing of progression. However, recent lixisenatide, ambroxol, ursodeoxycholic acid, LRRK2 inhibitors and prasenezumab trials have added valuable insights both in the biology and methodology of the field. The future of therapeutic development could be moving from treating the symptoms of a disease to modifying it, via the use of biomarker-driven and genetically defined trials. This review analyzes existing pharmacotherapies, novel delivery systems, and future pharmacologic options for improvement with a critical review of comparative efficacy, unmet challenges, unanswered controversies and priorities for continued research and development.

Zenodo (CERN European Organization for Nuclear Research)
Desh Bhagat University (IN)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon